The Motley Fool

1 US pot stock I might buy

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Powder of Cannabis (Drugs), Analysis of Cannabis in laboratory.
Image source: Getty Images

If I wanted to make an investment to follow the growing interest in pot stocks, then I’d look to the US public markets. Cannabis stocks are notoriously volatile. Nevertheless, the sector is showing signs of resilience, with M&A activity helping strengthen and merge key players.

Will Tilray become top dog?

Major pot stock Aphria (NASDAQ:APHA) has been given the green light from shareholders to acquire Canadian rival Tilray (NASDAQ:TLRY). This puts the wheels in motion for the world’s largest pot stock by revenue to take shape. Tilray shareholders still have to agree, but it’s looking increasingly likely. If the reverse takeover goes ahead, the new entity will be known as Tilray. But it will be Aphria’s CEO leading the new company and Aphria management will hold seven of the nine board seats.

5G is here – and shares of this ‘sleeping giant’ could be a great way for you to potentially profit!

According to one leading industry firm, the 5G boom could create a global industry worth US$12.3 TRILLION out of thin air…

And if you click here we’ll show you something that could be key to unlocking 5G’s full potential...

Aphria is dual-listed on the Toronto Stock Exchange and NASDAQ. Meanwhile, its closest rivals in the Canadian markets are Canopy Growth and Aurora Cannabis.

Growing acceptance

The medical marijuana sector has been gaining acceptance throughout the US and UK. And now pressure’s rising on Europe to better regulate it too. Hence, the region is gaining global appeal as the next market to expand into.

The Aphria/Tilray merger would put it in a powerful position to make inroads into the European sector. That’s because Aphria already has assets in Germany, while Tilray has a facility in Portugal.

In November, Aphria acquired SweetWater, an American craft beer company for $300m. Meanwhile, Tilray has also begun building a US presence through its acquisition of Manitoba Harvest. These brands should make it easier for the new company to expand throughout the US.

There’s also greater interest in pot stocks with anticipation the Biden administration will decriminalise the sector at the federal level.

Share price volatility continues

Aphria’s share price fell this week after Q3 sales and earnings per share came in lower than expected. This was due to Covid-19-related costs and loss of revenues from physical store closures.

Long-term risks shareholders should consider include the highly competitive landscape and the costs in distribution and running physical stores. A lot will depend on how long it takes for US states to legalise, for decriminalisation to come from the federal level, and how quickly Europe rolls out their medical marijuana regulatory framework. This could all take some time. Then there’s Covid-19, which may continue to cause disruption.

Should I buy Tilray or Aphria stock before the merger?

If I buy 100 Tilray shares today, it will cost me approximately $1,770. And, if I buy 100 Aphria shares today, it will cost me approximately $1,400.

Aphria may seem the obvious choice, as it’s cheaper, but when the companies merge, my Aphria shares will be converted at a rate of 0.8381. This means I would have approximately 83 shares of the new company. Whereas the number of Tilray shares I would own would stay the same. So, it very much depends on the share price at the time of purchase.

As long as the company can continue to make sales and expand, then the growth story could continue to be great for keeping the share price buoyant. But, I’d prefer to wait and see what the new company looks like after the merger goes through before investing.

Here's another US stock worth considering...

“This Stock Could Be Like Buying Amazon in 1997”

I'm sure you'll agree that's quite the statement from Motley Fool Co-Founder Tom Gardner.

But since our US analyst team first recommended shares in this unique tech stock back in 2016, the value has soared.

What's more, we firmly believe there's still plenty of upside in its future. In fact, even throughout the current coronavirus crisis, its performance has been beating Wall St expectations.

And right now, we're giving you a chance to discover exactly what has got our analysts all fired up about this niche industry phenomenon, in our FREE special report, A Top US Share From The Motley Fool.

Click here to claim your copy now — and we’ll tell you the name of this Top US Share… free of charge!

Kirsteen has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

Our 6 'Best Buys Now' Shares

Renowned stock-picker Mark Rogers and his analyst team at The Motley Fool UK have named 6 shares that they believe UK investors should consider buying NOW.

So if you’re looking for more stock ideas to try and best position your portfolio today, then it might be a good day for you. Because we're offering a full 33% off your first year of membership to our flagship share-tipping service, backed by our 'no quibbles' 30-day subscription fee refund guarantee.

Simply click below to discover how you can take advantage of this.